Table 3.

Profiles and responses of patients with metastatic breast cancer in a HF10 phase I clinical trial.

Patient No.	Age (years)	Recurrence region	Prior therapy	HF10 pfu/0.5 mL × 3 days	No. of Doses	Response	Side effects	Shedding
1	61	Skin, LN, lung, brain	CT-, HT-, RT-	1 × 104	1	Moderate response	None	No shedding into body fluids
2	62	Skin, LN	CT-, RT-	2 × 105	1	Mild response
3	48	Skin, LN, lung, bone	SR	3 × 105	3	Marked response
4	66	Skin, LN	CT-, HT-	5 × 105	1	Moderate response
5	72	Skin	S-, CT-, HT-	5 × 105	3	Complete response
6	76	Skin	CT-, HT-	5 × 105	3	Not applicable

CT, chemotherapy; HT, hormonal therapy; RT, radiotherapy; SR, surgery.